Conjunctivitis AllergicNCT07710846
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
An observational study of Conjunctivitis Allergic, run by Regeneron Pharmaceuticals.
Trial summary
The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen allergy clinical research studies in the future. Read more about this study
- Who is it for?
- Ages 5 years and older
- Conditions the study is for
- Conjunctivitis Allergic
- What is being tested?
- Noninterventional
- How many people
- 1,500 participants
- Where
- No sites listed yet
- Study dates
- 17 Aug 2026to 10 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study will enroll adult and pediatric (aged ≥5 to <18 years) participants with cat and/or birch allergen induced allergic conjunctivitis with or without allergic rhinitis
Who may be able to join
- Adults or pediatric participants, ≥5 years of age inclusive (pediatric participants ≥5 years and <18 years and weighing ≥10 kg, to be enrolled where permitted per local regulations/approvals), at the time of signing the informed consent
- Participant-reported (and/or caregiver-reported for pediatric participants) and/or documented allergic history as described in the protocol
- Positive Skin Prick Test (SPT) at screening: to cat allergen (Part A) and/or to birch allergen (Part B)
- Must not currently live with a cat(s) or have lived with a cat(s) in the home for the past 1 year (Part A)
- Willing and able to comply with clinic visit(s) and study-related assessments
Who cannot join
- Presence of any ophthalmic disease/abnormality/condition that may interfere with study assessments, affect the study outcomes or participant safety as described in the protocol
- History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, and/or hypoxic seizures
- Active, chronic infections requiring long-term use of systemic antibiotics, antivirals, or anti-fungal treatments
- Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Patient Identification and Characterization (PIC) Study: A Prospective, Multicenter, Non-Interventional Study to Identify and Characterize Participants With Allergic Conjunctivitis With or Without Allergic Rhinitis Due to Cat and/or Birch Allergy
The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen allergy clinical research studies in the future. The study is also looking at how cat and/or birch tree pollen allergies have affected overall health.
- Conditions
- Conjunctivitis Allergic
- Being tested
- Noninterventional
- Keywords
- Cat and/or birch allergen induced allergic conjunctivitis, Cat allergy, Birch pollen allergy, Eye allergy, Cat-induced eye allergy, Ocular allergy signs/symptoms, Allergic conjunctivitis signs/symptoms
- Medical subject headings
- Conjunctivitis, Allergic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NoninterventionalOther
No investigational medicinal products will be administered in this study.
| Study group | Role | What they receive |
|---|---|---|
| Part A | Cat allergy Receives: Other: Noninterventional | |
| Part B | Birch allergy Receives: Other: Noninterventional |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of participants with moderate-to-severe allergic conjunctivitis due to cat allergy who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander
Part A
Measured: At visit 1, up to 30 days
Proportion of participants with moderate-to-severe allergic conjunctivitis due to birch tree pollen allergy who report "very bothered" or "extremely bothered" by allergic symptoms
Part B
Measured: At visit 1, up to 30 days
Secondary outcomes (2)
Proportion of participants who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander
Part A
Measured: At visit 1, up to 30 days
Proportions of participants who report "very bothered" or "extremely bothered" by allergic symptoms due to birch tree pollen
Part B
Measured: At visit 1, up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start17 Aug 2026 (estimated)
- Primary completion10 Jan 2028 (estimated)
- Study completion10 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Conjunctivitis AllergicStudies of the same condition, open and under way.
- More trials run by Regeneron PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trial Management, Study director, Regeneron Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07710846
- Sponsor's protocol ID
- R1908-1909-ALG-25126
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Identification and Characterization (PIC) Study: A Prospective, Multicenter, Non-Interventional Study to Identify and Characterize Participants With Allergic Conjunctivitis With or Without Allergic Rhinitis Due to Cat and/or Birch Allergy
- ClinicalTrials.gov ID
- NCT07710846
- Acronym / sponsor ID
- R1908-1909-ALG-25126
- Conditions
- Conjunctivitis Allergic
- Keywords
- Cat and/or birch allergen induced allergic conjunctivitis, Cat allergy, Birch pollen allergy, Eye allergy, Cat-induced eye allergy, Ocular allergy signs/symptoms, Allergic conjunctivitis signs/symptoms
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Regeneron PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 17 Aug 2026 (estimated)
- Primary completion
- 10 Jan 2028 (estimated)
- Study completion
- 10 Jan 2028 (estimated)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen allergy clinical research studies in the future. The study is also looking at how cat and/or birch tree pollen allergies have affected overall health.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Part A | – | Other: NoninterventionalCat allergy |
| Part B | – | Other: NoninterventionalBirch allergy |
Who may qualify
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study will enroll adult and pediatric (aged ≥5 to <18 years) participants with cat and/or birch allergen induced allergic conjunctivitis with or without allergic rhinitis
Key inclusion criteria (5 listed)
- Adults or pediatric participants, ≥5 years of age inclusive (pediatric participants ≥5 years and <18 years and weighing ≥10 kg, to be enrolled where permitted per local regulations/approvals), at the time of signing the informed consent
- Participant-reported (and/or caregiver-reported for pediatric participants) and/or documented allergic history as described in the protocol
- Positive Skin Prick Test (SPT) at screening: to cat allergen (Part A) and/or to birch allergen (Part B)
- Must not currently live with a cat(s) or have lived with a cat(s) in the home for the past 1 year (Part A)
- Willing and able to comply with clinic visit(s) and study-related assessments
Key exclusion criteria (4 listed)
- Presence of any ophthalmic disease/abnormality/condition that may interfere with study assessments, affect the study outcomes or participant safety as described in the protocol
- History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, and/or hypoxic seizures
- Active, chronic infections requiring long-term use of systemic antibiotics, antivirals, or anti-fungal treatments
- Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NoninterventionalNo investigational medicinal products will be administered in this study. | Other | Part A, Part B |
Primary outcome
Proportion of participants with moderate-to-severe allergic conjunctivitis due to cat allergy who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander
Time frame: At visit 1, up to 30 days
Part A
Proportion of participants with moderate-to-severe allergic conjunctivitis due to birch tree pollen allergy who report "very bothered" or "extremely bothered" by allergic symptoms
Time frame: At visit 1, up to 30 days
Part B
2 secondary outcomes
Proportion of participants who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander
Time frame: At visit 1, up to 30 days
Proportions of participants who report "very bothered" or "extremely bothered" by allergic symptoms due to birch tree pollen
Time frame: At visit 1, up to 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Conjunctivitis Allergic
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
Allergic Conjunctivitis
Recruiting
Daydrop® Triple Action for Allergic Eye Symptoms
Allergic Conjunctivitis of Both Eyes
RecruitingPhase 3
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
Persistent Corneal Epithelial Defect
RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
RecruitingObservational study
Treatment of Ocular Surface Inflammations
Ocular Surface Allergy, Conjunctivitis, Allergic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Trial Management study director
Regeneron Pharmaceuticals
Questions about this trial
What is this clinical trial studying?
An observational study of Conjunctivitis Allergic, run by Regeneron Pharmaceuticals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Trials Administrator (844-734-6643, clinicaltrials@regeneron.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of participants with moderate-to-severe allergic conjunctivitis due to cat allergy who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander (time frame: At visit 1, up to 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.